Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Dexamethasone in BRVO (COMRADE-B)
NCT01396057Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2011
- Primary completion
- Jun 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in macular edema and branch retinal vein occlusion (BRVO) (2 arms), sponsored by Novartis. Primary endpoint: Mean Average Best Corrected Visual Acuity Change From Month 1 Through Month 6 to Baseline. Started Jul 2011; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edemabranch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on NCT01396057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01396057.